Previous close | 34.65 |
Open | 34.60 |
Bid | 39.20 |
Ask | 40.20 |
Strike | 155.00 |
Expiry date | 2026-01-16 |
Day's range | 34.60 - 34.65 |
Contract range | N/A |
Volume | |
Open interest | 258 |
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
Moderna revealed its combination flu/COVID vaccine performed better than the two shots independently.